Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TMEM202 antisense RNA 1 (TMEM202-AS1) is a long non-coding RNA (lncRNA) that is transcribed antisense to the TMEM202 gene[1][5]. Antisense lncRNAs often regulate the expression of their sense partner genes or other genes by affecting splicing, recruiting transcription factors, or modulating mRNA stability, but there is currently no published evidence for a direct functional or disease-related role of TMEM202-AS1 specifically[1][5][2]. It is identifiable in public databases (such as NCBI Gene accession 105370888), but is not considered a therapeutic target (its molecular function, disease relevance, and targetability are not established)[1][5]. If you are seeking structured data for TMEM202-AS1, it should be classified as an antisense lncRNA, with currently unknown physiological and disease linkages, not as an established receptor, enzyme, transporter, or similar druggable target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TMEM202 antisense RNA 1 (TMEM202-AS1).